Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)

This article was originally published in The Pink Sheet Daily

Executive Summary

Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.
Advertisement

Related Content

Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course
J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue
Schering-Plough Takes The Long Road To Early Stage Hep C R&D

Topics

Advertisement
UsernamePublicRestriction

Register

PS066110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel